Shaping a suitable EU HTA dossier template: why the German template is not fit for purpose
Authors:
- Maria Katharina SchweitzerMSMaria Katharina Schweitzer
- Manuel Nico DoldMDManuel Nico Dold
- Astrid GenetAGAstrid Genet
- Klaus GossensKGKlaus Gossens
- Thomas Klein-HesslingTKThomas Klein-Hessling
- Nils LöfflerNLNils Löffler
- Matthias RabelMRMatthias Rabel
- Andrej RaschARAndrej Rasch
- Jessica SchmelcherJSJessica Schmelcher
- Natalia WolframNWNatalia Wolfram
- Sebastian WernerSWSebastian Werner
Open Access
- 16 October 2023
- journal article
- research article
- Published by Springer Nature in The European Journal of Health Economics
- Vol. 25 (5) , 877-888
Abstract
From 2025, Health Technology Developers (HTDs) have to submit EU HTA dossiers. The joint clinical assessment (JCA) aims to streamline HTA processes and access to medicinal products across Europe. Currently, German HTA bodies IQWiG and G-BA actively shape the JCA methodology. Here we examine if German HTA dossier requirements are suitable for the JCA. We compare the number of safety endpoint and subgroup analyses in German dossiers with analyses considered in IQWIG’s benefit assessment and evaluate if these analyses were considered by the G-BA. We further investigated how the number of analyses was affected by the latest change in the German dossier template. With the current template, HTDs report in median 2.6 times more analyses on adverse events (AE) and 1.1 times more subgroup categories than in the previous template. IQWiG does not consider 33% of AE analyses and 73% of the subgroup categories presented by the HTD under the current template. G-BA considered the same AE as IQWiG in 76% of cases. Subgroups were uncommented by G-BA in most cases, independent of the template (previous: 93%, current 85%) and unconsidered in the conclusion on additional benefit (previous: 77%, current 69%). Thus, changes in the dossier template drastically increased HTD workload, but additional analyses seem unconsidered by the HTA bodies. With a broader scope in JCA, this effect could be amplified. To mitigate duplicative efforts and ensure prompt availability of medicinal products as envisioned by the HTAR, we suggest well-chosen and precise dossier requirements, early consultations, and early HTD engagement.Keywords
This publication has 13 references indexed in Scilit:
- Health Technology Assessment of Advanced Therapy Medicinal Products: Comparison Among 3 European CountriesFrontiers in Pharmacology, 2021
- Differences in Health Technology Assessment Recommendations Among European Jurisdictions: The Role of Practice VariationsValue in Health, 2020
- PNS167 QUANTITATIVE AND QUALITATIVE ANALYSIS OF DIFFERENCES IN AMNOG OUTCOMES BETWEEN IQWIG AND G-BA BETWEEN 2011-2018Value in Health, 2019
- Evidence-based decision-making for diagnostic and therapeutic methods: the changing landscape of assessment approaches in GermanyHealth Research Policy and Systems, 2017
- Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countriesThe European Journal of Health Economics, 2017
- Variation in Health Technology Assessment and Reimbursement Processes in EuropeValue in Health, 2017
- Health benefit assessment of pharmaceuticals: An international comparison of decisions from Germany, England, Scotland and AustraliaHealth Policy, 2016
- A Systematic Comparision of Iqwig Recommendations and G-Ba Decisions In The Amnog Process In GermanyValue in Health, 2015
- Comparison Of Iqwig and G-BA Benefit Ratings in OncologyValue in Health, 2014
- Requirements for benefit assessment in Germany and England – overview and comparisonHealth Economics Review, 2014